 

Active ingredient: Aliskiren Hemifumarate; Hydrochlorothiazide 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 3 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 300 mg/25 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comment: 




 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in-vivo 

Strength: 300 mg/25 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: The test and reference products should be administered 30 minutes after 
start of the meal. 




 

 

3. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 300 mg/12.5 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comment 




 

 

Analytes to measure: Aliskiren and hydrochlorothiazide in plasma 

 

Bioequivalence based on (90% CI): Aliskiren and hydrochlorothiazide 

 

Waiver request of in-vivo testing: 150 mg /25 mg; and 150 mg/12.5 mg based on (i) acceptable 
bioequivalence studies on the 300 mg/25 mg strength, (ii) acceptable dissolution testing across all 
strengths, and (iii) proportional similarity in the formulations across all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all 
strengths of the test and reference products. Specifications will be determined upon review of the 
application. 


